RTI Surgical Inc.
(RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today the full market launch of the Tritium Sternal Cable Plating (SCP) System for closing median sternotomies following open heart procedures.
The Tritium SCP System enhances the stability and strength of traditional sternal closure techniques by using a unique load-sharing concept. The device combines the advantages of cerclage cables and cancellous screws, integrated with a low profile plate. This unique combination creates a load-sharing design that uses cable tension to provide circumferential compression across the median sternotomy. The company received FDA clearance for the system in October 2012 and the first clinical use occurred in January 2013.
“The Tritium SCP System is the first implant launched since the acquisition of Pioneer Surgical Technology,” said Brian K. Hutchison, president and CEO of RTI Surgical. “This system is one of many exciting products RTI Surgical is launching this year and we are extremely pleased with the surgeon feedback we have seen so far.”
Dr. Steven D. Harrington, medical director of cardiothoracic surgery at Henry Ford Macomb Hospital, Clinton Township, MI, is one of the first to use the system following the full launch. According to Dr. Harrington, “The end result was a solid, tight sternal closure with a plating system that did not require extra dissection or devascularization of the sternum to achieve fixation and screw placement.”
“I have found the Tritium cable plate system to be one of the most secure and easy to use closure systems available,” said Dr. Harrington. “It provides that extra measure of stable approximation while being simple and straightforward to size and implant.”
For more information about the Tritium SCP System, please visit
, and to learn more about RTI Surgical please visit
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to advancing science, safety and innovation, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in more than 47 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of Advamed. For more information, please visit
Forward Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). In addition, these statements are subject to risks associated with the Pioneer’s financial condition, business and operations and the integration of Pioneer’s business with ours. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at
or the SEC’s website at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.